Sepsis-induced cardiomyopathy

Current Cardiology Reviews

Volumn 7, Issue 3, 2011, Pages 163-183

  Romero Bermejo, Francisco J ^a   Ruiz Bailen, Manuel ^b   Gil Cebrian, Julián ^a   Huertos Ranchal, María J ^a  

^a HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^b Intensive Care Unit   (Spain)

Author keywords

Cardiac depression; Heart failure; Myocardial dysfunction; Sepsis; Septic shock; Severe sepsis

Indexed keywords

AMLODIPINE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CD14 ANTIGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; FLUINDOSTATIN; GELATINASE A; GELATINASE B; INOTROPIC AGENT; LEVOSIMENDAN; MANIDIPINE; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; NICARDIPINE; NITRIC OXIDE; NORADRENALIN; OXYGEN RADICAL; PEROXYNITRITE; PROTEIN C; SIMVASTATIN; STEROID; SUPEROXIDE DISMUTASE; TERLIPRESSIN; TOLL LIKE RECEPTOR; TROPONIN I; UNINDEXED DRUG;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; ANAPHYLAXIS; APOPTOSIS; ASTHMA; BRAIN ISCHEMIA; BURN; CARDIOMYOPATHY; CLINICAL FEATURE; DIURESIS; ECHOCARDIOGRAPHY; ELECTROCONVULSIVE THERAPY; ETIOLOGY; FLUID RESUSCITATION; GLIA CELL; HEART ARREST; HEART ARRHYTHMIA; HEART INDEX; HEART PROTECTION; HEMORRHAGIC SHOCK; HUMAN; HYPERTENSIVE CRISIS; HYPERTHERMIA; HYPOCALCEMIA; HYPOTHERMIA; IMPEDANCE CARDIOGRAPHY; INTOXICATION; LUNG EMBOLISM; MALNUTRITION; MEAN ARTERIAL PRESSURE; MORTALITY; MUSCLE FIBRIL; NERVE CELL; NONHUMAN; OBSTRUCTIVE JAUNDICE; OXYGEN SATURATION; PANCREATITIS; PATHOPHYSIOLOGY; PHEOCHROMOCYTOMA; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; SEPSIS; SEPSIS INDUCED MYOCARDIAL DYSFUNCTION; SEPTIC SHOCK; STRANGULATION; STRESS; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; SYSTOLIC BLOOD PRESSURE; THYROID DISEASE; UPPER RESPIRATORY TRACT OBSTRUCTION;

ANIMALS; CALCIUM; CARDIOMYOPATHIES; HUMANS; MICROCIRCULATION; MYOCARDIAL ISCHEMIA; MYOCARDIUM; MYOFIBRILS; RECEPTORS, ADRENERGIC, BETA; SEPSIS; TOLL-LIKE RECEPTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR DYSFUNCTION, RIGHT;

EID: 82055162875     PISSN: 1573403X     EISSN: 18756557     Source Type: Journal    
DOI: 10.2174/157340311798220494     Document Type: Review

References (262)

1. Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365: 63-78.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 throught 2000. N Engl J Med 2003; 348: 1546-54.
3. Angus DC, Linde-Zwirble WT, et al. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29: 1303-10.
4. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35: 1244-50.
5. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34: 344-53.
6. Alberti C, Brun-Buisson C, et al. Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 2002; 28: 108-121.
7. Padkin A, Goldfrad C, Brady AR, et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003; 31: 2332-8.
8. Charpentier J, Luyt CE, Fulla Y, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepses. Crit Care Med 2004; 32: 660-65.
9. Vieillard-Baron A, Caille V, Charron C, Belliard G, Bernard Page, Jardin F. Actual incidence of global left ventricular hypokinesia in adult septic shock. Crit Care Med 2008; 36: 1701-6.
10. Levy MM, Dellinger RP, Townsend SR, et al. The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis. Intensive Care Med 2010; 36: 222-31).
11. Fernandes CJ, Akamine N, Knobel E. Cardiac troponin: A new serum marker of myocardial injury in sepsis. Intensive Care Med 1999; 25: 1165-1168.
12. Blanco J, Muriel-Bombin A, Sagredo V, et al. Incidence, organ dysfunction and mortality in severe sepsis: A Spanish multicentre study. Crit Care Med 2008; 12: R158.
13. Heindrickx GR, Millard RW, McRitchie RJ, et al. Regional myocardial function and electrophysiological alterations after brief coronary artery occlusion in conscious dogs. J Clin Invest 1975; 56: 978-985.
14. Braunwald E, Kloner RA. The stunned myocardium: Prolonged, postischemic ventricular dysfunction. Circulation 1982; 66: 1146-1149.
15. Clowes GH, Jr, Vucinic M, Weidner MG. Circulatory and metabolic alterations associated with survival or death in peritonitis: clinical analysis of 25 cases. Ann Surg 1966; 163: 866-85.
16. McLean LD, Mulligan WG, McLean AP, Duff JH. Patterns of septic shock in man -a detailed study of 56 patients. Ann Surg 1967; 166: 543-62.
17. Weisel RD, Vito L, Dennis RC, et al. Myocardial depression during sepsis. Am J Surg 1977; 133: 512-21.
18. Rackow EC, Kaufman BS, Falk JL, et al. Hemodynamic responses to fluid repletion in patients with septic shock: evidence for early depression of cardiac performance. Circ Shock 1987; 22: 11-22.
19. Abraham E, Shoemaker WC, Bland RD, Cobo JC. Sequential cardiorespiratory patterns in septic shock. Crit Care Med 1983; 11: 799-803.
20. Wilson RF, Sarver EJ, LeBlanc PL. Factors affecting hemodynamics in clinical shock with sepsis. Ann Surg 1971; 174: 939-43.
21. Parker MM, Shelhamer JH, Bacharach SL, et al. Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 1984; 100: 483-90.
22. Sharkey SW, Shear W, Hodges M, et al. Reversible myocardial contraction anomalies in patients with an acute noncardiac illness. Chest 1998; 114: 98-105.
23. Iga K, Hori K, Kitaguchi K, et al. Transient segmental asynergy of the left ventricle of patients with various clinical manifestations possibly untreated to the coronary artery disease. Jpn Cir J 1991; 55: 1061-7.
24. Ruiz-Bailen M. Reversible myocardial dysfunction in critically ill, noncardiac patients: A review. Crit Care Med 2002; 30: 1280-90.
25. Fernandes CJ Jr, Akamine N, Knobel E. Myocardial depression in sepsis. Shock 2008; 30: 14-17.
26. Price S, Anning PB, Mitchell JA, et al. Myocardial dysfunction in sepsis: Mechanisms and therapeutic implications. Eur Heart J 1999; 20: 715-24
27. Crews JR, Harrison K, Corey GR, et al. Stunned myocardium in the toxic shock syndrome. Ann Intern Med 1992; 117: 912-3
28. Jardin F, Brun-Ney D, Auvert B, et al: Sepsis-related cardiogenic shock. Crit Care 1990; 18: 1055-60.
29. Kumar A, Haery C, Parrillo JE. Myocardial dysfunction in septic shock. Crit Care Clin 2000; 16: 251-87.
30. Jardin F, Fourme T, Page B, et al: Persistent preload defect in severe sepsis despite fluid loading: A longitudinal echocardiographic study in patients with septic shock. Chest 1999; 116: 1354-9
31. Vincent JL, Gris P, Coffernils M, et al. Myocardial depression characterizes the fatal course of septic shock. Surgery 1992; 111: 660-7.
32. Vieillard-Baron A, Schmitt JM, Beauchet A, et al. Early preload adaptation in septic shock? A transesophageal echocardiographic study. Anesthesiology 2001; 94: 400-6
33. Bouhemad B, Nicolas-Robin A, Arbelot C, Arthaud M, Feger D, Rouby JJ. Acute left ventricular dilatation and shock-induce myocardial dysfunction. Crit Care Med 2009; 37: 441-7.
34. Zanotti-Cavazzoni SL, Guglielmi M, Parrillo JE, et al. Ventricular Dilation is Associated with Improved Cardiovascular Performance and Survival in Sepsis. Chest. 2010. [Epub ahead of print]
35. Parker MM, McCarthy KE, Ognibene FP, Parrillo JE. Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest. 1990; 97: 126-31.
36. Sibbald WJ, Paterson NA, Holliday RL, Anderson RA, Lobb TR, Duff JH. Pulmonary hypertension in sepsis: measurement by the pulmonary arterial diastolic - pulmonary wedge pressure gradient and the influence of passive and active factors. Chest 1978; 73(5): 583-91.
37. Calvin JE. Acute right heart failure: pathophysiology, recognition, and pharmacological management. J Cardiothorac Vasc Anesth 1991; 5: 508-13.
38. Vincent JL, Gris P, Coffernils M, et al. Myocardial depression characterizes the fatal course of septic shock. Surgery 1992; 111: 660-7.
39. Heindereich PA, Stainback RF, Redburg RF, et al. Transesophageal echocardiography predicts mortality in critically ill patients with unexplained hypotension. J Am Coll Cardiol 1995; 26: 152-8.
40. Poelaert J, Declerck C, Vogelaers D, et al. Left ventricylar systolic and diastolic function in septic shock. Intensive Care Med 1997; 23: 553-60.
41. Munt B, Jue J, Gin K, Fenwick J, Tweeddale M. Diastolic filling in human severe sepsis: an echocardiographic study. Crit Care Med 1998; 26: 1829-33
42. Jafri SM, Lavine S, Field BE, Bahorozian MT, Carlson RW. Left ventricular diastolic function in sepsis. Crit Care Med 1990; 18: 709-14
43. Lattik R, Couture P, Denault AY, et al. Mitral Doppler indices are superior to two-dimensional echocardiographic and hemodynamic variables in predicting responsiveness of cardiac output to a rapid intravenous infusion of colloid. Anest Analg 2002; 94: 1092-9.
44. Swenson JD, Harkin C, Pace NL, et al. Transesophageal echocardiography: an objective tool in defining maximum ventricular response to intravenous fluid therapy. Anesth Analg 1996; 83: 1149-53.
45. Mathru M, Pollar V, He G, et al. Left ventricular diastolic filling characteristics are not impaired but systolic performance was augmented in the early hours of experimental endotoxemia in humans. Shock 2006; 25(4): 338-43.
46. dos Santos CC, Gattas DJ, Tsoporis JN, et al. Sepsis-induced myocardial depression is associated with transcriptional changes in energy metabolism and contractile related genes: A physiological and gene expression-based approach. Crit Care Med 2010; 38: 894-902
47. Bruni FD, Komwatana P, Soulsby ME, Hess ML. Endotoxin and myocardial failure: role of the myofibril and venous return. Am J Physiol 1978; 235: H150.
48. Hinshaw LB, Archer LT, Spitzer JJ, et al. Effects of coronary hypotension and endotoxin on myocardial performance. Am J Physiol 1974; 227: 1051.
49. Cunnion RE, Schaer GL, Parker MM, et al. The coronary circulation in human septic shock. Circulation 1986; 73: 637-44
50. Dhainaut JE, Huyghebaert MF, Monsallier JF, et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987; 75: 533-41
51. Solomon MA, Correa R, Alexander HR, et al. Myocardial energy metabolism and morphology in a canine model of sepsis. Am J Physiol 1994; 266: H757-68
52. Wu AH. Increased troponin in patients with sepsis and septic shock: myocardial necrosis or reversible myocardial depression?. Intensive Care Med 2001; 27: 959-61
53. Groeneveld AB, van Lambalgen AA, van den Bos GC, Bronsveld W, Nauta JJ, Thijs LG. Maldistribution of heterogeneous coronary blood flow during canine endotoxin shock. Cardiovasc Res 1991; 25: 80-8
54. Madorin WS, Rui T, Sugimoto N, et al. Cardiac myocytes activated by septic plasma promote neutrophil transendotelial migration: role of platelet-activating factor and the chemokines LIX and KC. Circ Res 2004; 94: 944-51
55. Hotchkiss RS, Rust RS, Dence CS, et al. Evaluation of the role of celular hipoxia isn sepsis by the hypoxic marker [18F] fluoromisonidazole. Am J Physiol Regul Integr Comp Physiol 1991; 261: R965-72.
56. Lefer AM. Role of a myocardial depressant factor in the pathogenesis of circulatory shock. Fed Proc 1970; 29: 1836-47.
57. Wangensteen SL, Geissinger WT, Lovett WL, Glenn TM, Lefer AM. Relationship between splanchnic blood flow and a myocardial depressant factor in endotoxin shock. Surgery 1971; 69: 410-8.
58. Parrillo JE, Burch C, Shelhamer JH, Parker MM, Natanson C, Schuette W. A circulating myocardial depressant substance in humans with septic shock: septic shock patients with a reduced ejection fraction have a circulating factor that depresses in vitro myocardial cell performance. J Clin Invest 1985; 76: 1539-53.
59. Natanson C, Eichenholz PW, Danner RL, et al. Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 1989; 169: 823-32.
60. 2+]i and contractility in isolated adult rabbit ventricular myocytes. Am J Physiol 1996; 271: H1449-55.
61. Vincent JL, Bakker J, Marecaux G, Schandene L, Kahn RJ, Dupont E. Administration of anti.TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study. Chest 1992: 101: 810-5.
62. Kumar A, Thota V, Dee L, Olson J, Uretz E, Parrillo JE. Tumor necrosis factor alpha and interleukin 1 beta are responsible for in vitro myocardial cell depression induced by human septic shock serum. J Exp Med 1996; 183: 949-58.
63. Niederbichler AD, Hoesel LM, Westfall MV, et al. An essential role for complement C5a in the pathogenesis of septic cardiac disfunction. J Exp Med 2006; 203: 53-61.
64. Pathan N, Hemingway CA, Alizadeh AA, et al. Role of interleukin 6 in myocardial disfunction of meningococal septic shock. Lancet 2004; 363: 203-9.
65. Garner LB, Willis MS, Carlson DL, et al. Macrophage migration inhibitory factor is a cardiac-derived myocardial depressant factor. Am J Physiol Heart Circ Phisiol 2003; 285: H2500-9.
66. Chagnon F, Metz CN, Bucala R, et al. Endotoxin-induced myocardial disfunction: effects of macropha ge migration inhibitory factor neutralization. Circ Res 2005; 96: 1095-102.
67. Calandra T, Echtenacher B, Roy DL, et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 2000; 6: 164-70.
68. Abi-Gerges N, Tavernier B, Mebazaa A, et al. Sequential changes in autonomic regulation of cardiac myocytes after in vivo endotoxin injection in the rat. Am J Respir Crit Care Med 1999; 160: 1196-204.
69. Mebazaa A, De Keulenaer GW, Paqueron X, et al. Activation of cardiac endothelium as a compensatory component in endotoxin -induced cardiomyopathy: role of endotelin, prostaglandins and nitric oxide. Circulation 2001; 104: 3137-44.
70. Reilly JM, Cunnion RE, Burch-Wuitman C, Parker MM, Shelhamer JH, Parrillo JE. A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. Chest 1989; 95: 1072-80.
71. Rossi MA, Celes MR, Prado CM, et al. Myocardial structural changes in long-term human severe sepsis/septic shock may be responsable for cardiac dysfunction. Shock 2007; 27: 10-18
72. Levy RJ, Piel DA, Acton PD, et al. Evidence for myocardial hibernation in the septic heart. Crit Care Med 2005; 33: 2752-6.
73. Dhainaut JE, Huyghebaert MF, Monsallier JF, et al. Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 1987; 75: 533-41.
74. Kreymann G, Grosser S, Buggisch P, et al. Oxygen consumption and resting metabolic rate in sepsis, sepsis síndrome, and septic shock. Crit Care Med 1993; 21: 1012-29.
75. Boekstegers P, Weidenhöfer, S, Kapsner T, et al. Skeletal muscle partial pressure of oxygen in patients with sepsis and septic shock: Comparison to limited infection and cardiogenic shock. Infection 1991; 19: 317-23.
76. Sharshar T, Gray F, de la Grandmaison GL, et al. Apoptosis of neurons in cardiovascular autonomic centres triggered by inducible nitric oxyde synthase after death from deptic shock. Lancet 2003; 362: 1799-805.
77. Sharshar T, Annane D, de la Grandmaison Brouland, JP, Hopkinson NS, Françoise G. The neuropathology of septic shock. Brain Pathol 2004; 14: 21-33.
78. Annane D, Trabold F, Sharshar T, et al. Inappropiate sympathetic activation at onset of septic shock: a spectral analysis approach. Am J Respir Crit Care Med 1999; 160: 458-65.
79. Bernardin G, Strosberg AD, Bernard A, et al. β-adrenergic receptor-dependent and independent stimulation of adenylate ciclase is impaired during severe sepsis in humans. Intensive Care Med 1998; 24: 1315-22.
80. Opie LH. Receptors and signal transduction. In: Heart physiology: From Cell to Circulation. Fourth Edition. Opiet LH (Ed) London. Lippincott Williams & Wilkins. 2004: 86-220.
81. Azimi G, Vincent JL. Ultimate survival from septic shock. Resuscitation 1986; 14: 245-53.
82. Gu M, Bose R, Bose D, Yang J, Li X, Light RB, Mink S. Tumor necrosis factor-alpha, but not septic plasma depresses cardiac myofilament contraction. Can J Anaesth 1998; 45: 280-6.
83. Hosenpud JD, Campbell SM, Mendelson DJ. Interleukin-1 induced myocardial depressionin an isolated beating heart preparation. J Heart Transplant 1989; 8: 460-4.
84. Vincent JL, Bakker J, Marecaux G, Schandene L, Kahn RJ, Dupont E. Administration of anti-TNF antibody improves left ventricular function in septic shock patients: results of a pilot study. Chest 1992; 101: 810-5.
85. Opal SM, Fisher CJ Jr, Dhainaut JF, et al. Confirmatory interleukin- 1 receptor antagonist trial in severe sepsis: a phase III, randomized, double blind, placebo-controlled multicenter trial. The interleukin-1 receptor antagonist sepsis investigator group. Crit Care Med 1997; 25: 1115-24.
86. Abi-Gerges N, Tavernier B, Mehazaa A, et al. Sequential changes in autonomic regulation of cardiac myocytes after in vivo endotoxin injection in rat. Am J Respir Crit Care Med 1999; 160: 1196-204.
87. Zhong J, Hwang T-C, Adams HR, et al. Reduced L-type calcium current in ventricular myocytes from endotoxemic guinea pigs. Am J Physiol Heart Cir Physiol 1997; 273: 2312-24.
88. Liu S, Schreur KD. G protein-mediated suppression of L-type Ca2+ current by interleukin1-beta in cultured rat ventricular myocytes. Am J Physiol Cell Physiol 1995; 268: 339-49.
89. Buckley JF, Singer M, Clapp LH. Role of KATP channels in sepsis. Cardiovasc Res 2006; 72: 220-30.
90. Wu L-L, Liu M-S. Altered ryanodine receptor of canine cardiac sarcoplasmic reticulum and its underlying mechanism in endotoxin shock. J Surg Res 1992; 53: 82-90.
91. Dong LW, Wu L-L, Ji Y, et al. Impairment of the ryanodinesensitive calcium release channels in the cardiac sarcoplasmic reticulum and its underlying mechanism during the hypodynamic phase of sepsis. Shock 2001: 16: 33-9.
92. Cohen RI, Wilson D, Liu SF. Nitric oxyde modifies the sarcoplasmic reticular calcium release in endotoxemia by both guanosine-3'- 5' (cyclic) phosphate-dependent and independent pathways. Crit Care Med 2006; 34: 173-81.
93. Favory R, Lancel S, Marchetti P, et al. Endotoxin-induced myocardial dysfunction: evidence for a role of sphingosine production. Crit Care Med 2004; 32: 495-501.
94. Wu LL, Ji Y, Dong LW, Liu MS. Calcium uptake by the sarcoplasmic reticulum is impaired during the hypodynamic phase of sepsis in the rat heart. Shock 2001; 15: 49-55.
95. Wu LL, Tang C, Dong LW, Liu MS. Altered phospholambancalcium ATPase interaction in cardiac sarcoplasmic reticulum during the progression of sepsis. Shock 2002; 17: 389-93.
96. Chen HV, Hsu C, Lu TS, Wang SJ, Yang RC. Heat shock pretreatment prevents cardiac mitocondrial dysfunction during sepsis. Shock 2003; 20: 274-9.
97. Stuart RA, Cyr DM, Neupert W. Hsp 70 in mitocondrial biogénesis: from chaperoning nascent polypeptide chains to facilitation of protein degradation. Experientia 1994; 50: 1002-11.
98. Mizzen LA, Kabiling AN, Welch WJ. The two mammalian mitocondrial stress proteins, grp 75 y hsp 58, transiently interact with newly synthesized mitocondrial proteins. Cell Regul 1991; 2: 165-79.
99. Lew WY, Yasuda S, Yuan T, Hammond HK. Endotoxin-induced cardiac depression in associated with decreased cardiac dihydropyridine receptor in rabbits. J Mol Cell Cardiol 1996; 28: 1367-71.
100. Tavernier B, Mebazaa A, Mateo P, Sys S, Ventura-Clapier R, Veksler V. Phosphorilation-dependent alteration in myofilament Ca2+ sensitivity but normal mytochondrial function in septic heart. Am J Respir Crit Care Med 2001; 163: 362-7.
101. Shah AM. Paracrine modulation of heart cell function by endotelial cells. Cardiovasc Res 1996; 31: 847-67.
102. Rossi MA, Celes MR, Prado CM, Saggioro FP. Myocardial structural changes in long term human severe sepsis/sepsis shock may be responsable for cardiac dysfunction. Shock 2007; 27: 10-18.
103. Wang W, Schulze CJ, Suarez-Pinzon WL, et al. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002; 106: 1543-9.
104. Gao CQ, Sawicki G, Suarez-Pinzon WL, et al. Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 2003; 57: 426-33.
105. Baumgarten G, Knuefermann P Schuhmacher G, et al. Toll-like receptor 4, nitric oxyde and myocardial depression in endotoxemia. Shock 2006; 25: 43-9.
106. Knuefermann P, Nemoto S, Misra A, et al. CD-14 deficient mice are protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction. Circulation 2002; 106: 2608-15.
107. Thomas JA, Haudek SB, Koroglu T, et al. IRAF1 deletion disrupts cardiac Toll/Il-1 signaling and protects against contractile dysfunction. Am J Physiol Heart Circ Physiol 2003; 285: H597-H606.
108. Ferrero E, Jiao D, Tsuberi BZ, et al. Transgenic mice expressing human CD14 are hypersensitive to lipopolysaccharide. Proc Natl Acad SCI U.S.A. 1993; 90: 2380-4.
109. Haziot A, Ferrero E, Köntgen F, et al. Resistance to endotoxin shock and reduced dissemination of gram-negative bacteria in CD-14-deficient mice. Immunity 1996; 4: 407-14.
110. Knuefermann P, Nemoto S, Misra A, et al. CD-14 deficient mice are protected against lipopolysaccharide-induced cardiac inflammation and left ventricular dysfunction. Circulation 2002; 106: 2608-15.
111. Hahn PYng P, Tait SM, Ba ZF, Reich SS, Chaundry IH. Sustained elevation in circulating catecholamine levels during polymicrobian sepsis. Shock 1995; 4: 269-73.
112. Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF. Interleukin-1 and tumor necrosis factor inhibit cardiac myocyte betaadrenergic responsiveness. Proc Natl Acad Sci USA 1989; 86: 6753-7.
113. Matsuda N, Hattori Y, Akaishi Y, Suzuki Y, Kemmotsu O, Gando S. Impairment of cardiac beta-adrenoceptor celular signaling by decreased expression of G(s alpha) in septic rabbits. Anesthesiology 2000; 93: 1465-73.
114. Wu LL, Yang SL, Yang RC, et al. G protein and adenylate ciclase complex-mediated signal transduction in rat during sepsis. Shock 2003; 19: 533-7.
115. Bohm M, Kirchmayr R, Gierschik P, Erdmann E. Increase of myocardial inhibitory G-proteins in catecholamine-refractory septic shock or in septic multiorgan failure. Am J Med 1995; 98: 183-6.
116. Macarthur H, Westfall TC, Riley DP, et al. Inactivation of catecholamines by superoxyde gives news insights on the pathogenesis of septic shock. Proc Natl Acad Sci USA 2000; 97: 9753-8.
117. Hare JM, Loh E, Creager MA, et al. Nitric oxyde inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 1995; 92: 2198-203.
118. Barth E, Radermacher P, Thiemermann C, et al. Role of inducible nitric oxyde synthase in the reduced responsiveness of the myocardium to catecholamines in a hyperdynamic, murine model of septic shock. Crit Care Med 2006; 34: 307-13.
119. Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med 2009; 24(5): 293-316.
120. Kiriakis JM, Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 2001; 81: 807-69.
121. Cook SA, Dugden PH, Clerk A. Activation of c-Jun-N-terminal kinases and p38-mitogen-activated protein kinases in human heart failure secondary to ischaemic heart disease. J Mol Cell Cardiol 1999; 31: 1429-34.
122. Creemers EE, Cleutjens JP, Smiths JF, Daemen MJ. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res 2001; 89; 201-10.
123. Cheung PY, Sawicki G, Woxniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemiareperfusion injury in the heart. Circulation 2000; 101: 1833-9.
124. Lalu MM, Gao CQ, Schulz R. Matrix metalloproteinase inhibitors attenuate endotoxemia induced cardiac dysfunction: a potential role for MMP-9. Mol Cell Biochem 2003; 251: 61-6.
125. Wohlschlaeger J, Stubbe HD, Schmitx KJ, et al. Roles of MMP-2/MMP-9 in cardiac dysfunction during early multiple organ failure in an ovine animal model. Pathol Res Pract 2005; 201: 809-17.
126. Wang D, Wei J, Hsu K, et al. Effects of nitric oxide synthase inhibitors on systemic hypotension, cytokines and inducible nitric oxide synthase expression and lung injury following endotoxin administration in rats. J Biomed Sci 1999; 6(1): 28-35.
127. Yu Z, Ouyang JP, Li YP. Dexamethasone attenuated endotoxininduced acute lung injury through inhibiting expression of inducible nitric oxide synthase. Clin Hemorheol Microcirc. 2009; 41(2): 117-25.
128. Saraiva RM, Hare JM. Nitric oxide signaling in the cardiovascular system: implications for heart failure. Curr Opin Cardiol 2006; 21: 221-8.
129. Xu L, Eu JP, Meissner G, Stamler JS. Activation of the cardiac calcium release cannel (ryanodine receptor) by poly-Snitrosylation. Science 1998; 279: 234-7.
130. Zimmet JM, Hare JM. Nitroso-redox interactions in the cardiovascular system. Circulation 2006; 114: 1531-44.
131. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91 (phox)-containing NADPH oxidase in angiotensin IIinduced cardiac nypertrophy in mice. Circulation 2002; 105: 293-6.
132. Juffermans NP, Vervloet MG, Daemen-Gubbels CR, Binnekade JM, de Jong M, Groeneveld AB. A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide 2010; 15; 22(4): 275-80
133. Soriano FG, Nogueira AC, Caldini EG, et al. Potential role of poly (adenosine 5'-diphosphate-ribose) polymerase activation in the pathogenesis of myocardial contractile dysfunction associated with human septic shock. Crit Care Med 2006; 34: 1073-9.
134. Suliman HB, Welty-Wolf KE, Carraway MS, et al. Lipopolysaccharide induces oxidative cardiac mitocondrial damage and biogénesis. Cardiovasc Res 2004; 64: 279-88.
135. Larche J, Lancel S, Hassoun SM, et al. Inhibition of mitocondrial permeability transition prevents sepsis-induced myocardial dysfunction and mortality. J Am Coll Cardiol 2006; 48: 377-85.
136. Buerke U, Carter JM, Schlitt A, et al. Apoptosis contributes to septic cardiomyopathy and is imporved by simvastatin therapy. Shock 2008; 29: 497-503.
137. Lancel S, Joulin O, Favory R, et al. Ventricular myocyte caspases are directly responsable for endotoxin-induced cardiac dysfunction. Circulation 2005; 111: 2596-604.
138. Neviere R, Fauvel H, Chopin C, et al. Caspase inhibition prevents cardiac dysfunction and heart apoptosis in a rat model of sepsis. Am J Respir Crit Care Med 2001: 163: 218-25.
139. Levy MM, Fink MP, Marshall JC, et al. International Sepsis Definitions Conference. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-8.
140. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345: 1368-77.
141. Kuzkov VV, Kirov MY, Sovershaev MA, et al. Extravascular lung water determined with single transpulmonary thermodilution correlates with the severity of sepsis-induced acute lung injury. Crit Care Med 2006; 34: 1647-53.
142. Fernandez-Mondejar E, Guerrero-Lopez F, Colmenero M. How important is the measurement of extravascular lung water? Curr Opin Crit Care 2007; 13: 79-83.
143. Monnet X, Anguel N, Naudin B, Jabot J, Richard C, Teboul JL. Arterial pressure-based cardiac output in septic patients: different accuracy of pulse contour and uncalibrated pressure waveform devices. Crit Care 2010; 14(3): R109.
144. Martinez JD, Babu RB, Sharma G. Escherichia coli septic shock masquerading as ST-segment elevation myocardial infarction. Postgrad Med. 2009; 121(2): 102-5)
145. Ruiz-Bailen M, Aguayo-Hoyos E, Lopez-Martinez A, et al. Reversible myocardial dysfunction, a posible complication in critically ill patients without heart disease. J Crit Care 2003; 18: 245-52.
146. Ozier Y, Guéret P, Jardin F, et al. Twodimensional echocardiographic demonstration of acute myocardial depression in septic shock. Crit Care Med 1984; 12: 596-99
147. Charon C, Caille V, Jardin F, et al. Echocardiographic measurement of fluid responsiveness. Curr Opin Crit Care 2006; 12: 249-54.
148. Mahjoub Y, Pila C, Friggeri A, et al. Assessing fluid responsiveness in critically ill patients: false positive pulse pressure variation is detected by Doppler echocardiographic evaluation of the right ventricle. Crit Care Med 2009; 37(9): 2570-5.
149. Schefold JC, Storm C, Bercker S, et al. Inferior vena cava diameter correlates with invasive hemodynamic measures in mechanically ventilated intensive care unit patients with sepsis. J Emerg Med 2010; 38: 632-7.
150. Bendjelid K, Romand J. Fluid responsiveness in mechanically ventilated patients: a review of indices used in intensive care. Intensive Care Med 2003; 29: 352-60.
151. Michard F, Teboul JL. Predicting fluid responsiveness in ICU patients. A critical analysis of the evidence. Chest 2002; 121: 2000-8.
152. Feissel M, Michard F, Faller JP, et al. The respiratory variation in inferior vena cava diameter as a guide to fluid therapy. Intensive Care Med 2004; 30: 1834-7.
153. Vieillard-Baron A, Chergui K, Rabiller A, et al. Superior vena cava collapsibility as a gauge of volume status in ventilated septic patients. Intensive Care Med 2004; 30: 1734-9.
154. Monsalve F, Rucabado L, Salvador A, et al. Myocardial depression in septic shock caused by meningococcal infection. Crit Care Med 1984; 12: 1201-3.
155. Ellrodt AG, Riedinger MS, Kimchi A, et al. Left ventricular performance in septic shock, reversible segmental and global abnormalities. Am Heart J 1985; 110: 402-9.
156. Vignon P, Allot V, Lesage J, et al. Diagnosis of left ventricular diastolic dysfunction in the setting of acute changes in loading conditions. Crit Care. 2007; 11(2): R43.
157. Ommen SR, Nishimura RA, Appleton CP, et al. Clinical Utility of Doppler Echocardiography and Tissue Doppler Imaging in the Estimation of Left Ventricular Filling Pressures: A Comparative Simultaneous Doppler-Catheterization Study. Circulation 2000; 102; 1788-94.
158. Kim DH, Kim YJ, Kim HK, et al. Usefulness of mitral annulus velocity for the early detection of left ventricular dysfunction in a rat model of diabetic cardiomyopathy. J Cardiovasc Ultrasound. 2010; 18(1): 6-11.
159. Caille V, Amiel JB, Charron C, Belliard G, Vieillard-Baron A, Vignon P. Echocardiography: a help in the weaning process. Crit Care 2010; 14(3): R120.
160. Sturgess DJ, Marwick TH, Joyce C, et al. Prediction of hospital outcome in septic shock: a prospective comparison of tissue Doppler and cardiac biomarkers. Crit Care Med 2010; 14: R44
161. Ikonomidis I, Nikolau M, Dimopoulou I, et al. Association of left ventricular diastolic dysfunction with elevated NT-proBNP in general intensive care unit patients with preserved ejection fraction: A complementary role of Tissue Doppler imaging parameters and NT-proBNP levels for adverse outcome. Shock 2010; 33: 141-8.
162. Sturgess DJ, Marwick TH, Joyce C, et al. Prediction of hospital outcome in septic shock: a prospective comparison of tissue Doppler and cardiac biomarkers. Crit Care 2010; 14(2): R44
163. Jardin F, Farcot JC, Boisante L, et al. Influence of positive and expiratory pressure on left ventricular performance. N Engl J Med 1981; 304: 387-92.
164. Ueti OM, Camargo EE, Ueti AA, Lima-Filho EC, Nogueira EA. Assessment of right ventricular function with Doppler echocardiographic indices derived from tricuspid annular motion: comparison with radionuclide angiography. Heart 2002; 88: 244-8.
165. Saxena N, Rajagopalan N, Edelman K, Lopez-Candales A. Tricuspid annular systolic velocity: a useful measurement in determining right ventricular systolic function regardless of pulmonary artery pressures. Echocardiography. 2006; 23(9): 750-5.
166. Lossnitzer D, Steen H, Lehrke S, et al. 1113 MAPSE and TAPSE measured by MRI correlate with left and right ventricular ejection fraction and NTproBNP in patients with in dilated cardiomyopathy. Journal of Cardiovascular Magnetic Resonance 2008, 10(Suppl 1): A238.
167. Tei C, Dujardin KS, Hodge DO, Kyle RA, Tajik AJ, Seward JB. Doppler MPI combining systolic and diastolic myocardial performance: clinical value in cardiac amyloidosis. J Am Coll Cardiol 1996; 27: 658-64.
168. Bruch C, Schmermund A, Marin D, et al. Tei-Index in patients with mild-to-moderate congestive heart failure. Eur Heart J 2000; 21: 1888-95.
169. Sado D, Greaves K. Myocardial perfusion echocardiography: a novel use in the diagnosis of sepsis-induced left ventricular systolic impairment of the intensive care unit. Eur J Echocardiogr 2010; Epub ahead of print→ BUSCAR.
170. Vieillard-Baron A, Slama M, Cholley B, Janvier G, Vignon P. Echocardiography in the intensive care unit: from evolution to revolution? Intensive Care Med 2008; 34(2): 243-9.
171. Vallet B, Chopin C, Curtis SE. Prognostic value of the dobutamine test in patients with sepsis syndrome and normal lactate values. A prospective, multicenter study. Crit Care Med 1993; 21: 1868-75.
172. Rhodes A, Lamb FJ, Malagon I, et al. A prospective study of the use of a dobutamine stress test to identify outcome in patients with sepsis, severe sepsis or septic shock. Crit Care Med 1999; 27: 2361-6
173. Pérez-Valenzuela J, Ruiz-Bailén M, Ferrezuelo-Mata A, et al. Disfunción miocárdica reversible del paciente crítico. Med Intensiva 2010; 34 (Supl): 134.
174. Jellis C, Martin J, Narula J, Marwick TH. Assessment of nonischemic myocardial fibrosis. J Am Coll Cardiol 2010; 56(2): 89-97.
175. Napoli AM, Corl K, Gardiner F, Forcada A. Prognostic value of noninvasive measures of contractily in emergency department patients with severe sepsis and septic shock undergoing early goaldirected therapy. J Crit Care 2010. In press.
176. Hunt PJ, Espiner EA, Nicholls MG, et al. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab 1996; 81: 3871-6.
177. Witthaut R, Busch C, Fraunberger P, et al. Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock. Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med 2003; 29: 1696-702
178. Charpentier J, Luyt CE, Fulla Y, et al. Brain natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004; 32: 660-5.
179. Blankenberg S, McQueen MJ, Smieja M, et al. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006; 114: 201-8.
180. Schnabel R, Lubos E, Rupprecht HJ, et al. B-type natriuretic peptide and the risk of cardiovascular events and death in patients with stable angina: Results from the AtheroGene study. J Am Coll Cardiol 2006; 47: 552-8.
181. Tung RH, Garcia C, Morss AM, et al. Utility of B-type natriuretic peptide for the evaluation of intensive care unit shock. Crit Care Med 2004; 32(8): 1643-7.
182. Cuthbertson BH, Patel RR, Croal BL, Barclay J, Hillis GS. B-type natriuretic peptide and the predictioni of outcome in patients admitted to intensive care. Anaesthesia 2005; 60(1): 16-21.
183. Post F, Weilemann LS, Messow CM, et al. B-type natriuretic peptide as a marker for sepsis-induced myocardial depression in intensive care patients. Crit Care Med 2008; 36: 3030-7.
184. Hartemink KJ, Twisk JW, Groeneveld AB. High circulating Nterminal pro-B-type natriuretic peptide is associated with greater systolic cardiac dysfunction and nonresponsiveness to fluids in septic vs nonseptic critically ill patients. J Crit Care. 2010. [Epub ahead of print]
185. Ammann P, Maggiorini M, Bertel O, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol 2003; 41: 2004-9.
186. Altmann DR, Korte W, Maeder MT, et al. Elevated cardiac troponin I in sepsis and septic shock: No evidence for thrombus associated myocardial necrosis. PLos ONE 5(2): e9017
187. Arlati S, Brenna S, Prencipe L, et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: A prospective study. Intensive Care Med 2000; 26: 31-7.
188. ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP, Gorus FK. Cardiac Troponins I and T Are Biological Markers of Left Ventricular Dysfunction in Septic Shock. Clin Chem 2000; 46: 650-7.
189. Ammann P, Fehr T, Minder EI, et al. Elevation of troponin I in sepsis and septic shock. Intensive Care Med 2001; 27: 965-9.
190. Mehta NJ, Khan IA, Gupta V, et al. Cardiac troponin I predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol 2004; 95: 13-7.
191. John J, Awab A, Norman D, et al. Activated protein C improves survival in severe sepsis patients with elevated troponin. Intensive Care Med 2007; 33: 2122-8.
192. Maeder M, Fehr T, Rickli H, et al. Sepsis-associated myocardial dysfunction: diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest 2006; 129: 1349-66
193. John J, Woodward B, Wang Y, et al. Troponin-I as a prognosticator of mortality in severe sepsis patients. J Crit Care (2010) 25, 270-5.
194. Bernard GR, Vincent JL, Laterre PJ, et al. For the recombinant human activated protein C worldwide evaluation in severe sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709.
195. Yucel T, Memis D, Karamanlioglu B, Sut N, Yuksel M. The prognostic value of atrial and brain natriuretic peptides, troponin I and C-reactive protein in patients withs sepsis. Exp Clin Cardiol 2008; 13(4): 183-8.
196. Ruiz-Bailen M, Perez-Valenzuela J, Ferrezuelo-Mata A, Obra- Cuadra RJ. Effect of the administration of statins in non-cardiac critical disease. Med Intensiva 2010. [Epub ahead of print]. doi: 10.1016/j.medin.2010.05.007)
197. Galderisi M. Echocardiographic evaluation of diastolic dysfunction and diastolic heart failure. Salud(i)Ciencia 15(5): 814-8.
198. Hollenberg SM. Vasopressor Support in Septic Shock. Chest 2007; 132(5): 1678-87.
199. Povoa P, Carneiro AH. Adrenergic support in septic shock: a critical review. Hosp Pract (Monneap) 2010; 38(1): 62-73.
200. Levy, B, Bollaert, PE, Charpentier, C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997; 23: 282-7.
201. Martin, C, Viviand, X, Arnaud, S, et al. Effects of norepinephrine plus dobutamine or norepinephrine alone on left ventricular performance of septic shock patients. Crit Care Med 1999; 27: 1708-13.
202. Hamzaoui O, Georger JF, Monnet X, et al. Early administration of norepinephrine increases cardiac preload and cardiac output in septic patients with life-threatening hypotension. Crit Care. 2010; 29; 14(4): R142.
203. Dünser MW, Hasibeder WR. Sympathetic overstimulation during critical illness: adverse effects of adrenergic stress. J Intensive Care Med 2009; 24(5): 293-316.
204. Regnier B, Rapin M, Gory G, et al. Haemodynamic effects of dopamine in septic shock. Intensive Care Med 1977; 3: 47-53.
205. Wilson RF, Sibbald WJ, Jaanimagi JL. Hemodynamic effects of dopamine in critically ill septic patients. J Surg Res 1976; 20: 163-72.
206. Sakr Y, Reinhart K, Vincent JL, et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study. Crit Care Med 2006; 34: 589-97.
207. De Backer D, Biston P, Devriendt J, et al. SOAP II Investigators: Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010; 362: 779-89.
208. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008; 34(1): 17-60.
209. Vincent JL, Roman A, Kahn RJ. Dobutamine administration in septic shock: addition to a standard protocol. Critical Care Medicine 1990; 18: 689-93.
210. Jardin F, Sportiche M, Bazin M, et al. Dobutamine: a hemodynamic evaluation in human septic shock. Crit Care Med 1981; 9: 329-32.
211. De Backer D, Berre J, Zhang H, et al. Relationship between oxygen uptake and oxygen delivery in septic patients: effects of prostacyclin versus dobutamine. Crit Care Med 1993; 21: 1658-64.
212. Wilson SJ, Mehta SS, Bellamy MC. The safety and efficacy of the use of vasopressin in sepsis and septic shock. Expert Opin Drug Saf 2005; 4(6): 1027-39.
213. Schmidt C, Hochert K, Kurt B, et al. Role of nuclear factorkappaB- dependent induction of cytokines in the regulation of vasopressin V1A-receptor during cecal ligation and puncture-induced circulatory failure. Crit Care Med 2008; 36: 2363-72.
214. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusión in patients with septic shock. N Engl J Med 2008; 358: 877-87.
215. Lange M, Ertmer C, Westphal M. Vasopressin vs. Terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med 2008; 34(5): 821-32.
216. Morelli A, Ertmer C, Lange M, et al. Effects of short-term simultaneous infusión of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth 2008; 100: 494-503.
217. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe lowoutput heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202.
218. Mebazaa A, Barraud D, Welschbillig S. Randomized clinical trials with levosimendan. Am J Cardiol 2005; 96 (suppl): 74G-9G.
219. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure (The SURVIVE Randomized Trial). JAMA 2007; 297: 1883-91.
220. Oldner A, Konrad D, Weitzberg E, et al. Effects of levosimendan, a novel inotropic calcium sensitizing drug, in experimental septic shock. Crit Care Med 2001; 29: 2185-93.
221. Faivre V, Kaskos H, Callebert J, et al. Cardiac and renal effects of levosimendam, arginine vasopressin, and norepinephrine in lipopolysaccharidetreated rabbits. Anesthesiology 2005; 103: 514-21.
222. Dubin A, Murias G, Sottile JP, et al. Effects of levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study. Intensive Care Med 2007; 33: 485-94.
223. Cunha-Goncalves D, Perez-de-Sa V, Dahm P, et al. Cardiovascular effects of levosimendan in the early stages of endotoxemia. Shock 2007; 28: 71-7.
224. Barraud D, Faivre V, Damy T, et al. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharidetreated rabbits: Comparison with dobutamine and milrinone. Crit Care Med 2007; 35: 1376-82.
225. Matejovic M, Krouzecky A, Radej J, Novak I. Successful reversal of resistant hypodinamic septic shock with levosimendan. Acta Anaesthesiol Scand 2005; 49: 127.
226. Noto A, Giacomini M, Palandi A, et al. Levosimendan in septic cardiac failure. Intensive Care Med 2005; 31: 164-5.
227. Powell BP, De Keulenaer BL. Levosimendan in septic shock: a case series. Br J Anaesth 2007; 99: 447-8.
228. Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005; 31(5): 638-44.
229. Morelli A, Teboul JL, Maggiore SM, et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006; 34(9): 2287-93.
230. Berk JL, Hagen JF, Beyer WH, Gerber MJ, Dochat GR. The treatment of endotoxin shock by beta adrenergic blockade. Ann Surg 1969; 169: 74-81.
231. Berk JL, Hagen JF, Dunn J. The role of beta adrenergic blockade in the treatment of septic shock. Surg Gynecol Obstet 1970; 130: 1025-34.
232. Herndon DN, Hart DW, Wolf SE, et al. Reversal of catabolism by β-blockade after severe burns. N Engl J Med 2001 25; 345: 1223-9.
233. Lechat P, Packer M, Chalon S, et al. Clinical effects of betaadrenergic blockade in chronic heart failure: A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98: 1184-91.
234. Friese RS, Barber R, McBride D, Bender J, Gentilello LM. Could beta blockade improve outcome after injury by modulating inflammatory profiles? J Trauma 2008; 64: 1061-8.
235. Rough J, Engdahl R, Opperman K, Yerrum S, Monroy MA, Daly JM. Beta2 Adrenoreceptor blockade attenuates the hyperinflammatory response induced by traumatic injury. Surgery 2009; 145(2): 235-42.
236. Salim A, Hadjizacharia P, Brown C, et al. Significance of troponin elevation after severe traumatic brain injury. J Trauma 2008; 64: 1061-8.
237. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335: 1713-20.
238. Suzuki T, Morisaki H, Serita R, et al. Infusion of beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005; 33: 2294-301.
239. Piper RD, Li FY, Myers ML, Sibbald WJ. Effects of isoproterenol on myocardial structure and function in septic rats. J Appl Physiol 1999; 86: 993-1001.
240. Ackland GL, Yao ST, Rudiger A, Dyson A, et al. Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1- adrenoceptor blockade in severe sepsis in rats. Crit Care Med 2010; 38(2): 388-94.
241. Hagiwara S, Iwasaka H, Maeda H, Noguchi T. Landiolol, an ultrashort- acting beta1-adrenoceptor antagonist, has protective effects in an LPS-induced systemic inflammation model. Shock 2009; 31(5): 515-20.
242. Gore DC, Wolfe RR. Hemodynamic and metabolic effects of selective beta1 adrenergic blockade during sepsis. Surgery 2006; 139: 686-94.
243. Schmittinger CA, Dünser MW, Haller M, et al. Combined milrinone and enteral metoprolol therapy in patients with septic myocardial depression. Crit Care med 2008; 12(4): R99.
244. Gutierrez J, Hossam A, Lazarezcu R, Kay E, Rundek T. Effect of beta blockers on sepsis outcome. Med Sci Monit. 2009; 15(10): CR499-503.
245. Jerwood S, Cohen J. Unexpected antimicrobial effect of statins. J Antimicrob Chemother. 2008; 61: 362-4.
246. Hackam D, Mamadani M, Li P, Redelmeier DA. Statins and Sepsis in patients with cardiovascular disease: a population-based cohort analysis. Lancet.2006; 367: 413-8.
247. Almog Y, Shefer A, Novack V, et al. Prior statin therapy is associated with a decreased rate of severe sepsis. Circulation. 2004; 110: 880-5.
248. Matthew E, Falagas ME, Makris G, Matthaiou DK, Rafailidis PI. Statins for infection and sepsis: a systematic review of the clinical. J Antimicrob Chemother.2008; 61: 774-85.
249. Kopterides P, Falagas ME. Statins for sepsis: a critical and updated review. Clin Microbiol Infect.2009; 15: 325-34.
250. Novack V, Eisinger M, Frenkel A, et al. The effects of statin therapy on inflammatory cytokines in patients with bacterial infections: a randomized double-blind placebo controlled clinical trial. Intensive CareMed. 2009; 35: 1255-60.
251. Mustafa SB, Olson MS. Effects of calcium cannel antagonist on LPS-induced hepatic iNOS expression. Am J Physiol 1999; 277: 351-60.
252. Xiao-Qiang L, Wei C, Tao L, et al. Amlodipine inhibits TNF-β production and attenuates cardiac dysfunction induced by lipopolysaccharide involving PI3K/Akt pathway. International Inmmunopharmacology 2009; 9: 1032-41.
253. Christoph A, Prondzinsky R, Russ M, et al. Early and sustained haemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Card Care 2008; 10: 49-57.
254. Pribble CG, Shaddy RE. Intra-aortic counterpulsation in newborn lambs infected with group B streptococcus. ASAIO Trans 1991; 37: 33-7.
255. Engoren M, Habib RH. Effects of intraaortic augmentation in a porcine model of endotoxemic shock. Resuscitation 2004; 60: 319-26.
256. Solomon SB, Minneci PC, Deans KJ, et al. Effects of intra-aortic balloon counterpulsation in a model of septic shock. Crit Care Med 2009; 37: 7-18.
257. Wendan K. Intra-aortic balloon counterpulsation in septic shock - really? Crit Care Med 2009; 37: 325-6.
258. Garatti A, Colombo T, Russo C, et al. Left ventricular mechanical support with the Impella Recover left direct microaxial blood pump: a single-center experience. Artif Organs 2006 Jul; 30(7): 523-8.
259. Berry MF, Pirolli TJ, Jayasankar V, et al. Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 2004; 110: II187-93.
260. Pan CS, Teng X, Zhang J, et al. Apelin Antagonizes Myocardial Impairment in Sepsis. J Cardiac Fail 2010; 16: 609-17.
261. Weil BR, Manukyan MC, Herrmann JL, et al. Mesenchymal stem cells attenuate myocardial functional depression and reduce systemic and myocardial inflammation during endotoxemia. Surgery 2010; 148: 444-52.
262. Neethling WM, Hodge AJ. The effect of diazepam on myocardial function and coronary vascular tone after endotoxemia in the isolated rat heart model. Inflamm Res 2010. [Epub ahead of print]